Inventor · disambiguated record
Istvan Enyedy
Also filed as: ENYEDY ISTVAN · ENYEDY ISTVAN J
8 granted patents·8 pending applications·145 citations·filing 2000–2022
85Inventor score
Files withBIOGEN MA INC5GEORGETOWN UNIVERSITY SCHOOL O2UNIV MICHIGAN2BAYER PHARMACEUTICALS CORP1BLACK DIAMOND THERAPEUTICS INC1
Top patents by PatentIndex Score
16 records- 0194US6703382B2Small molecule inhibitors targeted at Bcl-2UNIV GEORGETOWN MED CENTER·Filed 2001·Granted Mar 9, 2004·81 cites·8 claims
- 0287US7354928B2Small molecule inhibitors targeted at Bcl-2UNIV MICHIGAN·Filed 2002·Granted Apr 8, 2008·22 cites·20 claims
- 0387US7355015B1Matriptase, a serine protease and its applicationsGEORGETOWN UNIVERSITY SCHOOL O·Filed 2000·Granted Apr 8, 2008·27 cites·7 claims
- 0474US6677377B2Structure based discovery of inhibitors of matriptase for the treatment of cancer and other conditionsGEORGETOWN UNIVERSITY SCHOOL O·Filed 2001·Granted Jan 13, 2004·15 cites·23 claims
- 0565US2008058322A1Small molecule inhibitors targeted at Bcl-2UNIV MICHIGAN·Filed 2007·Application pending·0 cites
- 0661US2022048884A1Nrf2 activatorBIOGEN MA INC·Filed 2021·Application pending·0 cites
- 0758US2021340107A1Nrf2 activatorBIOGEN MA INC·Filed 2021·Application pending·0 cites
- 0855US7960163B2Matriptase, a serine protease and its applicationsGEORGETOWN UNIVERSITY SCHOOL OF MEDICINE·Filed 2008·Granted Jun 14, 2011·0 cites·3 claims
- 0953US7427689B2ErbB-2 selective small molecule kinase inhibitorsUNIV GEORGETOWN·Filed 2001·Granted Sep 23, 2008·0 cites·3 claims
- 1052US10968181B2NRF2 activatorBIOGEN MA INC·Filed 2017·Granted Apr 6, 2021·0 cites·24 claims
- 1152US2019389836A1Nrf2 activatorBIOGEN MA INC·Filed 2018·Application pending·0 cites
- 1250US2024317752A16-substituted-9h-purine derivatives and related usesBLACK DIAMOND THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1347US10301265B2Small molecule inhibitors of botulinum neurotoxinsROXAS DUNCAN VIRGINIA I·Filed 2009·Granted May 28, 2019·0 cites·6 claims
- 1444US2022089592A1Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitorsBIOGEN MA INC·Filed 2020·Application pending·0 cites
- 1542US2008293696A12-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic AgentsBAYER PHARMACEUTICALS CORP·Filed 2005·Application pending·0 cites
- 1639US2019256471A1Small molecule inhibitors of botulinum neurotoxinsTHE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE AR·Filed 2019·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →